Kymera Therapeutics


Kymera Therapeutics is pioneering a game-changing new therapeutic modality and platform with the potential to transform drug discovery and deliver breakthrough medicines for previously untreatable diseases. Kymera’s breakthrough therapeutics hijack and redirect the ubiquitin proteosome system (UPS), central to the regulation of cellular processes and the molecular biology of protein degradation. Using a small molecule-based knockdown strategy, we rationally design and develop heterobifunctional molecules or chimeras. These molecules recruit otherwise intractable disease-causing proteins to E3 ubiquitin ligases, resulting in the protein’s ubiquitination and subsequent degradation.

See all Members